Machin P J, Hurst D N, Bradshaw R M, Blaber L C, Burden D T, Melarange R A
J Med Chem. 1984 Apr;27(4):503-9. doi: 10.1021/jm00370a012.
A series of 4-substituted phenoxypropanolamines has been prepared and examined for beta-adrenoceptor activity. The 4-substituents, di- and triazole ring systems connected to the phenoxy ring by different length chains, were chosen as a means of introducing cardioselectivity. This has been achieved, especially in the 1-[4-[(4-chloropyrazol-1-yl)methoxy] phenoxy]-3-(isopropylamino)-2-propanol (11), the 4-[(2H-1,2,3-triazol-2-yl)methoxy] analogue (21), and the 4-[2-(2H-1,2,3-triazol-2-yl)ethoxy] analogue (22), which show potent beta 1-blockade with selectivity ratios in excess of 100:1. Structure-activity relationships are discussed, and the optimum position of the heteroatom in the 4-substituent is defined.
已制备了一系列4-取代苯氧基丙醇胺,并对其β-肾上腺素受体活性进行了研究。选择通过不同长度链与苯氧基环相连的4-取代基、二唑和三唑环系统作为引入心脏选择性的手段。这一点已经实现,特别是在1-[4-[(4-氯吡唑-1-基)甲氧基]苯氧基]-3-(异丙氨基)-2-丙醇(11)、4-[(2H-1,2,3-三唑-2-基)甲氧基]类似物(21)和4-[2-(2H-1,2,3-三唑-2-基)乙氧基]类似物(22)中,它们表现出强效的β1阻断作用,选择性比超过100:1。讨论了构效关系,并确定了4-取代基中杂原子的最佳位置。